Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03561376 · ClinicalTrials.gov registry record · Early Phase 1

Zinc Oxide Versus Petrolatum Following Skin Surgery

A Early Phase 1 study of Surgical Site Infection and Surgical Wound, sponsored by Melissa Pugliano-Mauro.

Recruiting
Registry status
Early Phase 1
Development phase
30
Enrollment target
1
Study location

NCT03561376: Recruiting Early Phase 1 study of Surgical Site Infection and Surgical Wound, sponsored by Melissa Pugliano-Mauro.

NCT03561376 is a Early Phase 1 study of Surgical Site Infection and Surgical Wound that is actively recruiting participants, run by Melissa Pugliano-Mauro. The registered enrollment target is 30 participants, below the 567-participant average among 25 other Surgical Site Infection trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03561376, a Early Phase 1 study of Surgical Site Infection and Surgical Wound, is actively recruiting participants, sponsored by Melissa Pugliano-Mauro.

RECRUITING
Registry status
Early Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Patients undergoing routine surgery in the Department of Dermatology for any indication on non-scalp skin and closed in linear fashion with scar greater than or equal to 4.5cm in length will be invited to participate in this split scar, head to head study comparing zinc oxide and petrolatum. Patients will apply respective ointments to each half of scar daily for one month and maintain a log of these activities. They will be seen at 1 week, 4 weeks, 8 weeks, and 6 months post-operatively for photographic scar assessment and to complete the patient portion of the Patient and Observer Scar Assessment Scale (POSAS), a quantitative objective assessment of scar appearance. Trained observers (board-certified dermatologists) will score the observer portion of the scale. POSAS outcomes, post-operative infections, linear density of epidermal seal will be assessed at the 1 week, 4 weeks, 8 weeks, and 6 months post-operative periods and compared between the two groups. Participants will have parking validated for all visits and upon completion of all portions of the study will receive a standardized skin care gift bag containing samples for hypoallergenic skin care products (washes, moisturizers, etc.).

Primary Outcome

Patient and observer scar assessment score. Range from 6-60. Higher score indicates greater patient satisfaction and better overall cosmesis of scar. Please note there is an observer and patient POSAS score. Both range from 6-60. The observer scale grades the apparent vascularity, pigmentation, thickness, relief, pliability, and surface area of the scar. The patient scale evaluate the patient's perception of pain, itching, color, stiffness, thickness, irregularity associated with the scar. Each

Interventions

  • DRUG Topical zinc oxide vs. petrolatum post-surgical scars

Study Locations (1)

Pennsylvania

  • UPMC Dermatology St. Margaret - Pittsburgh, PA

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-09-01
Est. Completion 2026-10-30
Phase Early Phase 1
Melissa Pugliano-Mauro

3 total trials

What NCT03561376 shows while recruiting

NCT03561376 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 567-participant average among 25 other Surgical Site Infection trials with a reported enrollment target (95% lower).

The record links to 6 conditions, with Surgical Site Infection appearing as the primary indexed condition, and to 1 intervention - of which Topical zinc oxide vs. petrolatum post-surgical scars is the first listed.

NCT03561376 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03561376 about?

NCT03561376 is a clinical study titled "Zinc Oxide Versus Petrolatum Following Skin Surgery". Patients undergoing routine surgery in the Department of Dermatology for any indication on non-scalp skin and closed in linear fashion with scar greater than or equal to 4.5cm in length will be invited to participate in this split scar, head to head study comparing zinc oxide and petrolatum. Patient...

What is the current status of trial NCT03561376?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2021-09-01. Estimated completion is 2026-10-30.

What conditions does trial NCT03561376 study?

This clinical trial studies the following conditions: Surgical Site Infection, Surgical Wound, Scar, Surgery--Complications, Hypertrophic Scar.

What interventions are being tested in trial NCT03561376?

The interventions under investigation include: Topical zinc oxide vs. petrolatum post-surgical scars (DRUG).

Who is sponsoring clinical trial NCT03561376?

This trial is sponsored by Melissa Pugliano-Mauro, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03561376 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Surgical Site Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03561376's enrollment target sits among peer trials

30 24th of 25 higher than 2 of 25 other Surgical Site Infection trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Surgical Site Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03561376, the US trial registry maintained by the National Library of Medicine. NCT03561376 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.